Paul Stoffels, Galapagos CEO (Andrew Harnik/AP Images)

Gala­pa­gos sends some em­ploy­ees — and a re­search unit — off to drug dis­cov­ery CRO as part of re­org

Paul Stof­fels has made it clear that he views cut­ting jobs at Gala­pa­gos as dif­fi­cult but nec­es­sary — but he’s get­ting cre­ative about it.

Gala­pa­gos, head­quar­tered in Meche­len, Bel­gium, has struck an arrange­ment with French con­tract re­search or­ga­ni­za­tion No­vAl­iX to trans­fer its drug dis­cov­ery and re­search ac­tiv­i­ties. While No­vAl­iX is based in Stras­bourg, it will take over run­ning the site that Gala­pa­gos ran in Ro­mainville, France.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters